Characterization of Biological Nanoparticle Subsets

生物纳米颗粒子集的表征

• 批准号: 10486870
• 负责人: Jennifer Jones
• 金额: $ 112.64万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10486870
• 关键词: Area; Biological; Biological Assay; Biology; Biomedical Research; Biophysics; Blood Tests; Blood Vessels; CCR; Cancer Patient; Clinical; Collaborations; Communities; Computer software; Detection; Disease; Epitopes; Foundations; Future; Goals; Immune; Immune response; Immunobiology; Investigation; Knowledge; Label; Laboratories; Legal patent; Malignant Neoplasms; Measures; Medicine; Methods; Mission; Molecular; Monitor; Neoplasm Circulating Cells; Nucleic Acids; Optical Instrument; Patient Care; Radiation; Reproducibility; Research; Resolution; System; Tumor Biology; Virus; Vision; Work; analysis pipeline; anticancer research; base; biological systems; exosome; extracellular vesicles; frontier; improved; interest; liquid biopsy; macromolecular assembly; microvesicles; multiple omics; nano; nanobiology; nanoparticle; nanoscale; neglect; neoplastic cell; next generation; novel; particle; programs; submicron; tool; treatment response; treatment strategy; tumor; tumor progression

Liquid biopsies are part of this emerging frontier in biomedical research. This frontier is of interest to all areas of biology and medicine and is of particular interest to the cancer research community. Circulating tumor cells (CTCs) and cell-free nucleic acids (cfNAs) are two types of liquid biopsies where clear progress has been made in the past decade towards understanding these CTC and cfNA tumor-related and systems-based biological information. Systematic, accurate, and reproducible studies of sub-micron extracellular vesicles (EVs) and other nanoscale macromolecular assemblies (collectively referred to hereafter as extracellular vesicles and particles, or EVPs) are difficult to perform due to a lack of robust and reliable tools for correctly measuring these submicron and nanoscale materials. CCR's mission is to improve the lives of all cancer patients by solving important, challenging, and neglected problems in cancer research and patient care. The Translational Nanobiology Section's particular expertise, perspective, collaborations, and vision within CCR is building bridges to span the existing gaps between basic biophysical and metrological first principles, advanced molecular multi-omics strategies, and clinical translational investigation in order to develop systematic, robust, and accurate ways to study EVPs tumor-, immune-, and stromal-/vascular- EVP compositions as they relate to tumor progression and treatment response in our cancer patients. Although the specific focus of my lab pertains most immediately to cancer and cancer-related immunobiology, we intend for our work to be a general asset to the biomedical research community. As such, my Section is committed to sharing our tools for general research use, so that they can accelerate studies in other diseases as well. The ultimate goal of my program is to leverage the information content in EVPs to interrogate biological systems in a systematic manner, that is, by identification and characterization of specific sub-sets of EVPs to 'read' the status of compartments represented by those sub-sets. The purpose of Projects 1 and 2 in the Translational Nanobiology Lab is to develop and demonstrate the use of new tools for the field to use that will enable us to monitor tumor, immune, and vascular/stromal systems in a manner that we hope will enable us to perform blood tests to detect relevant changes in those systems early in the course of radiation or other therapies, and we hope that this will more broadly serve as a foundation for enabling selectively (system-specific) adaptive treatment strategies in the future. Project 1 is focused on spanning the gap in available tools and knowledge to accurately characterize the liquid biopsy components, EVPs and their cargo, for Project 2.

液体活检是生物医学研究中这一新兴前沿领域的一部分。这一前沿是感兴趣的所有领域的生物学和医学，是特别感兴趣的癌症研究界。循环肿瘤细胞（CTC）和无细胞核酸（cfNA）是两种类型的液体活检，在过去十年中，在理解这些CTC和cfNA肿瘤相关和基于系统的生物信息方面取得了明显进展。亚微米细胞外囊泡（EV）和其他纳米级大分子组装体（以下统称为细胞外囊泡和颗粒或EVP）的系统、准确和可再现的研究难以进行，这是由于缺乏用于正确测量这些亚微米和纳米级材料的稳健和可靠的工具。CCR的使命是通过解决癌症研究和患者护理中重要的、具有挑战性的和被忽视的问题来改善所有癌症患者的生活。翻译纳米生物学部分的特殊专业知识，观点，合作和CCR内的愿景正在建立桥梁，以跨越基本生物物理学和生物学第一原则，先进的分子多组学策略和临床转化研究之间的现有差距，以开发系统，稳健和准确的方法来研究EVP肿瘤，免疫，和基质-/血管- EVP组合物，因为它们与我们的癌症患者中的肿瘤进展和治疗反应有关。虽然我的实验室的具体重点涉及最直接的癌症和癌症相关的免疫生物学，我们打算为我们的工作是一个一般的资产，以生物医学研究界。因此，我的科致力于分享我们的工具，供一般研究使用，以便它们也能加速其他疾病的研究。我的计划的最终目标是利用EVP中的信息内容以系统的方式询问生物系统，也就是说，通过识别和表征EVP的特定子集来“读取”这些子集所代表的隔间的状态。在转化纳米生物学实验室的项目1和2的目的是开发和展示新工具的使用，使我们能够监测肿瘤，免疫和血管/基质系统的方式，我们希望将使我们能够进行血液测试，以检测这些系统的相关变化早期在辐射或其他治疗的过程中，我们希望这将更广泛地作为未来选择性（系统特异性）适应性治疗策略的基础。项目1的重点是跨越可用工具和知识的差距，以准确表征项目2的液体活检组件、EVP及其货物。